Galderma R&D
Clinical trials sponsored by Galderma R&D, explained in plain language.
Dermatology-focused pharmaceutical company developing skin treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Sculptra shots aim to smooth cheek wrinkles in new study Results expected Sep 2026 (estimated)
- New drug shows promise for chronic itch in Long-Term trial Results expected Oct 2026 (estimated)
- Menopausal Women's skin changes under microscope in new study Results expected Nov 2026 (estimated)
- New Real-World study tests nemolizumab for persistent eczema itch Results expected Nov 2026 (estimated)
- New drug targets mysterious chronic itch Results expected Dec 2026 (estimated)
-
Can a new biologic calm severe eczema?
Disease control Not yet recruitingThis clinical trial is testing whether the drug nemolizumab can help treat moderate-to-severe atopic dermatitis (a common type of eczema) in Chinese patients aged 12 and older. Participants will receive either nemolizumab or a placebo (a look-alike with no active drug) every four…
Phase 3 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a gel injection sharpen the jawline? a trial puts it to the test
Symptom relief Not yet recruitingResearchers are testing whether Restylane Shaype, an injectable gel made of hyaluronic acid, can improve jawline definition in Chinese adults. The study includes about 162 participants aged 18 and older who want treatment on both sides of their jaw. Two-thirds receive the gel, wh…
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC